Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients

Wolf, Julie Ryan; Heckler, Charles E.; Guido, Joseph J.; Peoples, Anita R.; Gewandter, Jennifer S.; Ling, Marilyn N.; Vinciguerra, Vincent; Anderson, Thomas; Evans, Lisa; Wade, James L.; Pentland, Alice P.; Morrow, Gary R.

doi:10.1007/s00520-017-3957-4

Cited by 49 publications

(33 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The absence of changes in QoL scores indicates the absence of toxicities related to curcumin intake, which has also been shown in other studies (1, 55). However, in a randomized controlled trial, curcuminoid supplementation was associated with a significant improvement in QoL compared to placebo (56).…”

Section: Discussionsupporting

confidence: 85%

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer

et al. 2019

View full text Add to dashboard Cite

Curcumin is a botanical with anti-tumor and immunomodulatory properties. We hypothesized that curcumin supplementation might influence inflammatory biomarker levels in endometrial carcinoma (EC). In this open-label, non-randomized phase 2 study (NCT02017353), seven EC patients consumed 2 g/day Curcumin Phytosome (CP) orally for 2 weeks. Blood was taken at baseline, days 1, 7, 14, and 21. The following analytes were measured: curcuminoids and metabolites, 56 inflammatory biomarkers, COX-2, frequencies of myeloid-derived suppressor cells, dendritic cells and NK cells, expression of MHC molecules on leukocytes and monocytes and activation/memory status of T cells. Patients completed quality of life (QoL) questionnaires at baseline and end of treatment. Curcumin metabolites were detectable in plasma upon CP intake. CP downregulated MHC expression levels on leukocytes (P = 0.0313), the frequency of monocytes (P = 0.0114) and ICOS expression by CD8+ T cells (P = 0.0002). However, CP upregulated CD69 levels on CD16− NK cells (P = 0.0313). No differences were observed regarding inflammatory biomarkers, frequencies of other immune cell types, T cell activation and COX-2 expression. A non-significant trend to improved QoL was observed. Overall, CP-induced immunomodulatory effects in EC were modest without significant QoL changes. Given the small population and the observed variability in inter-patient biomarker levels, more research is necessary to explore whether benefits of CP can be obtained in EC by different supplementation regimens.Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT02017353; www.clinicaltrialsregister.eu, identifier 2013-001737-40.

show abstract

Section: Discussionsupporting

confidence: 85%

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Later, Ryan et al observed the protection of oral curcumin (6 g/day) administration vs. placebo after 6 months against radiation dermatitis in BC patients (n = 30) with prescribed radiation therapy (RT) [134]. The same authors tried to confirm their previous exploratory results in an ambitious trial that enrolled 686 patients with prescribed RT [135]. Nevertheless, curcumin did not reduce radiation dermatitis severity at the end of RT compared to placebo after 6 months (30 RT sessions).…”

Section: Dietary (Poly)phenols and Clinical Studies In Breast Cancer mentioning

confidence: 99%

Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives

Ávila‐Gálvez

Giménez‐Bastida

Espı́n

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy and the leading cause of cancer-related death in adult women worldwide. Over 85% of BC cases are non-hereditary, caused by modifiable extrinsic factors related to lifestyle, including dietary habits, which play a crucial role in cancer prevention. Although many epidemiological and observational studies have inversely correlated the fruit and vegetable consumption with the BC incidence, the involvement of their phenolic content in this correlation remains contradictory. During decades, wrong approaches that did not consider the bioavailability, metabolism, and breast tissue distribution of dietary phenolics persist behind the large currently existing gap between preclinical and clinical research. In the present review, we provide comprehensive preclinical and clinical evidence according to physiologically relevant in vitro and in vivo studies. Some dietary phenolics such as resveratrol (RSV), quercetin, isoflavones, epigallocatechin gallate (EGCG), lignans, and curcumin are gaining attention for their chemopreventive properties in preclinical research. However, the clinical evidence of dietary phenolics as BC chemopreventive compounds is still inconclusive. Therefore, the only way to validate promising preclinical results is to conduct clinical trials in BC patients. In this regard, future perspectives on dietary phenolics and BC research are also critically discussed.

show abstract

“…COX-2 is known to participate in uncontrolled cell proliferation and suppression of apoptosis, while inducible nitric oxide synthase (iNOS) and matrix metalloproteinase-9 (MMP-9) are involved in the formation of metastases [147,148]. Several studies, both in vitro and in vivo, demonstrated that the inhibitory action of curcumin on COX-2 expression contributes significantly to its antitumor action [72,80,126]. Curcumin was also shown to inhibit the expression of MMP-9 in orthotopically implanted pancreatic [129] and ovarian [130] tumors in mice and the production of iNOS in chronic colitis [127].…”

Section: Curcumin Regulates the Activity Of Enzymes With Roles In Inflammation And Cancermentioning

confidence: 99%

“…Some authors claim that serum levels of free curcumin show a deceivingly low bioavailability because a significant fraction of the compound occurs in plasma as glucuronide and sulfate conjugates [72,158]. In the abovementioned clinical study with patients taking 3.6 g of curcumin, serum levels of the conjugates averaged 0.016 µM for curcumin glucuronide and 0.009 for curcumin sulphate [152].…”

Section: Oral Administrationmentioning

confidence: 99%

“…Curcumin was evaluated in two clinical trials regarding protective action against radiation-induced dermatitis during radiotherapy of breast cancer patients. Despite promising results on a pilot study, with slightly less severe dermatitis in the curcumin group, a second trial on 686 patients showed no significant changes in pain, symptoms, and quality of life of the patients taking curcumin (1.5 g daily) in regard to those taking placebo [72]. • Pancreatic cancer, in the advanced stage, is a condition with very poor prognosis.…”

mentioning

confidence: 96%

See 1 more Smart Citation

Curcumin Innovative Delivery Forms: Paving the ‘Yellow Brick Road’ of Antitumoral Phytotherapy

2020

View full text Add to dashboard Cite

This review deals with the various aspects involved in the medicinal action of curcumin, from the photosensitivity and its relevance to storage and shelf-life, to the different routes of administration, which influence the bioavailability. The focus of the review is on the antitumor properties of curcumin and the currently available solutions for their amelioration. The work starts by presenting a brief historical perspective on the origins and uses of curcumin, from early days until the present time. The following sections describe the physico-chemical properties of curcumin and their impact on the biological activity and pharmacokinetics, raising awareness to the need for formulations able to improve the bioavailability. The last section is focused on research efforts being made to circumvent curcumin’s instability and low availability due to the extensive hepatic first pass metabolism, describing innovative scientific advances and new patented formulations and emerging products on the market.

show abstract

Oral curcumin for radiation dermatitis: a URCC NCORP study of 686 breast cancer patients

Cited by 49 publications

References 46 publications

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer

A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer

Dietary Phenolics against Breast Cancer. A Critical Evidence-Based Review and Future Perspectives

Curcumin Innovative Delivery Forms: Paving the ‘Yellow Brick Road’ of Antitumoral Phytotherapy

Contact Info

Product

Resources

About